Activated Prothrombin Complex Concentrates (aPCCs)

How to Cite This Chapter: Morin P-A, Ning S. Activated Prothrombin Complex Concentrates (aPCCs) . McMaster Textbook of Internal Medicine. Kraków: Medycyna Praktyczna. Accessed July 15, 2024.
Last Updated: October 19, 2023
Last Reviewed: October 19, 2023
Chapter Information

Activated prothrombin complex concentrates (aPCCs; factor VIII inhibitor bypassing activity [FEIBA]) contain mainly nonactivated therapeutic levels of factor II, IX, and X and mainly activated factor VII (VIIa).

Indications Top

1. Treatment of bleeding in individuals with congenital hemophilia A complicated by an inhibitor, who are not treated with emicizumab, and with acquired hemophilia A.

2. Off-label use: Intracranial hemorrhage, pentasaccharide-mediated (eg, fondaparinux) bleeding, life-threatening bleeding associated with non–vitamin K antagonists, reversal of dabigatran in patients who require urgent procedure (if idarucizumab is unavailable). 

aPCCs carry a prothrombotic risk and should only be administered in situations where the benefit of the therapy outweighs this risk.

We would love to hear from you

Comments, mistakes, suggestions?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.